NCT06152393View on ClinicalTrials.gov

Value of an Intrathecal Synthesis Index of Specific Antitreponema IgG for Neurosyphilis Diagnosis

CompletedOBSERVATIONAL

Enrollment

181

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Neurosyphilis

Interventions

DIAGNOSTIC_TEST

Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.

"Paired CSF/serum samples from all patients were blind tested for anti-T. pallidum IgG with an ELISA containing recombinant T. pallidum proteins (Euroimmun).~The AI was calculated conforming to Reiber's method (PMID 11239944) and as previously described in Alberto et al. (PMID 35138118)."

Trial Locations (1)

1204

Laurence Toutous Trellu, Geneva

All Listed Sponsors

collaborator

Swiss HIV Cohort Study

NETWORK

collaborator

Swiss National Science Foundation

OTHER

lead

University Hospital, Geneva

OTHER

NCT06152393 - Value of an Intrathecal Synthesis Index of Specific Antitreponema IgG for Neurosyphilis Diagnosis | Biotech Hunter | Biotech Hunter